Skip to main navigation Skip to search Skip to main content

Safety and efficacy of viramidine versus ribavirin in ViSER2: Randomized, double-blind study in therapy-naive hepatitis C patients

  • Patrick Marcellin
  • , Robert G. Gish
  • , Norman Gitlin
  • , Jamie Heise
  • , Deanine G. Halliman
  • , Eric Chun
  • , Maribel Rodriguez-Torres

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalJournal of Hepatology
Volume52
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

ASJC Scopus Subject Areas

  • Hepatology

Keywords

  • Anemia
  • Antiviral therapy
  • Hepatitis C
  • Sustained virologic response
  • Viramidine
  • Weight-based dosing
  • Humans
  • Middle Aged
  • Polyethylene Glycols/therapeutic use
  • Male
  • Anemia/epidemiology
  • Recombinant Proteins
  • Interferon-alpha/therapeutic use
  • Incidence
  • Dose-Response Relationship, Drug
  • Endpoint Determination
  • Adult
  • Female
  • Hepatitis C, Chronic/drug therapy
  • Drug Therapy, Combination
  • Double-Blind Method
  • Hepacivirus/genetics
  • RNA, Viral/genetics
  • Genotype
  • Treatment Outcome
  • Diarrhea/etiology
  • Antiviral Agents/adverse effects
  • Interferon alpha-2
  • Ribavirin/adverse effects

Cite this